Title:
【発明の名称】芳香族スルホンヒドロキサム酸メタロプロテアーゼ阻害剤
Document Type and Number:
Japanese Patent JP2001523662
Kind Code:
A
Abstract:
A treatment process is disclosed that comprises administering an effective amount of an aromatic sulfone hydroxamic acid that exhibits excellent inhibitory activity of one or more matrix metalloprotease (MMP) enzymes, such as MMP-2, MMP-9, and MMP-13, while exhibiting substantially less inhibition at least of MMP-1 to a host having a condition associated with pathological matrix metalloprotease activity. The administered enzyme inhibitor corresponds in structure to formula (I), below, or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are both hydrido or R1 and R2 together with the atoms to which they are bonded form a 5- to 8-membered ring containing one, two, or three heteroatoms in the ring that are oxygen, sulfur, or nitrogen. R3 in formula (I) is an optionally substituted aryl or optionally substituted heteroaryl radical. Also disclosed are metalloprotease inhibitor compounds having those selective activities, processes for manufacture of such compounds and pharmaceutical compositions using an inhibitor.
Inventors:
Bata, Thomas Y
Becker, Daniel Pea
Behm, Teri El
De Crescienzo, Gary Ay
Villa Mill, Clara Eye
McDonald, Joseph Jay
Frescos, John N
Getman, Daniel Pea
Becker, Daniel Pea
Behm, Teri El
De Crescienzo, Gary Ay
Villa Mill, Clara Eye
McDonald, Joseph Jay
Frescos, John N
Getman, Daniel Pea
Application Number:
JP2000521071A
Publication Date:
November 27, 2001
Filing Date:
November 12, 1998
Export Citation:
Assignee:
G.D.Searl and Company
International Classes:
A61K31/16; A61K31/167; A61K31/27; A61K31/35; A61K31/351; A61K31/357; A61K31/366; A61K31/38; A61K31/381; A61K31/382; A61K31/39; A61K31/4427; A61K31/443; A61K31/4433; A61K31/444; A61K31/445; A61K31/4465; A61K31/4525; A61K31/454; A61K31/496; A61K31/505; A61K31/506; A61K31/5375; A61K31/54; A61K31/541; A61P1/02; A61P1/04; A61P9/10; A61P13/00; A61P19/00; A61P19/02; A61P25/28; A61P27/02; A61P29/00; A61P35/00; A61P35/04; A61P43/00; C07C317/44; C07C319/06; C07D211/66; C07D211/94; C07D211/96; C07D239/04; C07D279/06; C07D309/08; C07D309/12; C07D319/06; C07D327/02; C07D333/38; C07D335/02; C07D337/04; C07D401/06; C07D401/12; C07D405/12; C07D405/14; C07D407/12; C07D409/12; C07D409/14; C07D413/06; C07D413/12; C07D413/14; C07D417/12; C07D521/00; (IPC1-7): A61K31/16; A61K31/167; A61K31/27; A61K31/35; A61K31/351; A61K31/357; A61K31/366; A61K31/38; A61K31/381; A61K31/382; A61K31/39; A61K31/444; A61K31/445; A61K31/4525; A61K31/454; A61K31/496; A61K31/505; A61K31/506; A61K31/5375; A61K31/54; A61K31/541; A61P1/02; A61P1/04; A61P9/10; A61P13/00; A61P19/00; A61P19/02; A61P25/28; A61P27/02; A61P29/00; A61P35/00; A61P35/04; A61P43/00; C07C319/06; C07D211/66; C07D239/04; C07D279/06; C07D309/08; C07D309/12; C07D327/02; C07D333/38; C07D335/02; C07D337/04; C07D401/06; C07D401/12; C07D405/12; C07D405/14; C07D407/12; C07D409/12; C07D409/14; C07D413/06; C07D413/12; C07D413/14; C07D417/12
Attorney, Agent or Firm:
Kazuo Shamoto (5 outside)